Scottish gene control specialist Synpromics Ltd has entered into a collaborative agreement with University College London (UCL) to develop a gene therapy for Parkinson's disease, the company announced on Tuesday.
The pair will work to create an array of synthetic, novel gene promoters for the central nervous system (CNS), with the aim of generating a gene therapy.
The gene promoters can theoretically specifically control the expression of therapeutic genes in different sub-populations of neurones. UCL hopes that they can be used to advance a gene therapy-based approach for the treatment of young-onset Parkinson's disease.
Commenting on the news, Dr Michael Roberts, founder and chief scientific officer of Synpromics, stated: "Tightly controlling the therapeutic gene is an essential element in the development of any successful gene therapy and Synpromics' technology offers the best means to achieve that control.
"This collaboration will allow the company to develop a gene therapy approach for a largely unmet clinical need, where tight gene control is an absolute requirement. It also gives us the opportunity to work with UCL, one of the few world-leading institutions actively developing novel gene-based therapies."
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference